MedElevator
Войти в исследования Clinical therapeutics · 2025
Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Patients With Coronary Heart Disease and Heart Failure Treated With Empagliflozin.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
El-Sherbeni Ahmed A, Khedr Naglaa F, Khairat Ibtsam, Werida Rehab H
Аннотация
PURPOSE: Coronary artery disease (CAD) and heart failure (HF) are leading causes of global morbidity and mortality and pose economic burden. This study aims to examine the diagnostic and prognostic significance of biomarkers in patients with CAD and HF treated with empagliflozin.
METHODS: In a prospective, case-control study, 180 participants were divided into 3 groups: patients with stable angina (CAD) and patients with HF on empagliflozin 10 mg daily for 6 months compared with healthy controls. Biomarker levels were measured at baseline, with hospital readmission rates monitored over 30 and 90 days. Stepwise logistic regression was used to predict hospital readmissions with and without participant clinical features. All relevant independent variables were then included in a single model using multiple logistic regression.
FINDINGS: Significant differences in biomarker profiles were observed across groups, indicating the differential significance of these biomarkers in diagnostic and prognostic aspects. Multinomial logistic regression identified 3 biomarkers as key diagnostic markers for CAD and HF: homocysteine (relative risk ratio [RRR] = 16.5 for CAD), fetuin A (RRR = 1.1 for HF), and visfatin (RRR = 30.4 and 23.1 for CAD and HF, respectively). Prognostic analysis by multiple logistic regression identified visfatin (odds ratio = 6.5) and high-sensitivity C-reactive protein (odds ratio = 1.9) as significant predictors of hospital readmission for patients with CAD and HF, respectively.
IMPLICATIONS: The study underscores the promising role of selected biomarkers in the diagnosis and prognosis of CAD and HF diseases. These findings suggest the integration of biomarker profiling into clinical protocols to enhance patient care and outcomes in cardiovascular disease, especially in those treated with empagliflozin. Even if these indicators have potential, further larger size, long-term research is required to confirm their use in clinical settings.
CLINICALTRIALS: gov identifier: NCT05911724.
METHODS: In a prospective, case-control study, 180 participants were divided into 3 groups: patients with stable angina (CAD) and patients with HF on empagliflozin 10 mg daily for 6 months compared with healthy controls. Biomarker levels were measured at baseline, with hospital readmission rates monitored over 30 and 90 days. Stepwise logistic regression was used to predict hospital readmissions with and without participant clinical features. All relevant independent variables were then included in a single model using multiple logistic regression.
FINDINGS: Significant differences in biomarker profiles were observed across groups, indicating the differential significance of these biomarkers in diagnostic and prognostic aspects. Multinomial logistic regression identified 3 biomarkers as key diagnostic markers for CAD and HF: homocysteine (relative risk ratio [RRR] = 16.5 for CAD), fetuin A (RRR = 1.1 for HF), and visfatin (RRR = 30.4 and 23.1 for CAD and HF, respectively). Prognostic analysis by multiple logistic regression identified visfatin (odds ratio = 6.5) and high-sensitivity C-reactive protein (odds ratio = 1.9) as significant predictors of hospital readmission for patients with CAD and HF, respectively.
IMPLICATIONS: The study underscores the promising role of selected biomarkers in the diagnosis and prognosis of CAD and HF diseases. These findings suggest the integration of biomarker profiling into clinical protocols to enhance patient care and outcomes in cardiovascular disease, especially in those treated with empagliflozin. Even if these indicators have potential, further larger size, long-term research is required to confirm their use in clinical settings.
CLINICALTRIALS: gov identifier: NCT05911724.